Paper Details

  1. Home
  2. Paper Details

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Author: BinetJ L, CazinB, DesablensB, DighieroG, DreyfusB, JaubertJ, LeblayR, LepeuG, LeporrierM, MaloumK, NavarroM, TravadeP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Two randomized trials found that chlorambucil treatment did not increase survival in patients with indolent chronic lymphocytic leukemia (CLL). The studies suggest that treatment of indolent CLL is unnecessary and that deferring therapy until the disease progresses does not compromise survival.
Paper Details　
Original Abstract of the Article :
BACKGROUND: To determine whether chlorambucil treatment benefits patients with indolent chronic lymphocytic leukemia (CLL), we conducted two randomized trials in 1535 patients with previously untreated stage A CLL. METHODS: In the first trial, 609 patients were randomly assigned to receive either d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM199805213382104

データ提供：米国国立医学図書館（NLM）

Chlorambucil for Indolent Chronic Lymphocytic Leukemia: Rethinking Treatment Strategies

The field of [chronic lymphocytic leukemia (CLL)] treatment continues to evolve, with ongoing research into the most effective therapies. This study investigated the efficacy of chlorambucil in treating indolent CLL. The authors conducted two randomized trials involving a large number of patients, comparing the outcomes of chlorambucil treatment with those of no treatment.

Chlorambucil: No Survival Benefit for Indolent CLL

The study found no significant improvement in overall survival for patients with indolent CLL who received chlorambucil treatment compared to those who did not. While chlorambucil was effective in slowing disease progression, it did not impact survival. The authors concluded that treatment of indolent CLL with chlorambucil is unnecessary, as deferring therapy until the disease progresses does not compromise survival.

Navigating the CLL Treatment Landscape

CLL is a complex disease, and treatment decisions must be carefully considered. This study provides valuable information about the potential benefits and limitations of chlorambucil for indolent CLL. It emphasizes the importance of individualizing treatment plans based on disease stage, patient preferences, and potential risks and benefits. Just as a camel adapts to the diverse terrain of the desert, clinicians must adapt their treatment strategies to the unique needs of each patient with CLL.

Dr.Camel's Conclusion

The study's findings offer a new perspective on the treatment of indolent CLL, suggesting that delaying therapy until the disease progresses may be a viable option. The research highlights the importance of ongoing research and careful consideration of treatment decisions in the context of individual patient needs. Just as a camel must adapt to the unpredictable changes of the desert, the field of medicine must continue to evolve and adapt to ensure optimal patient care.

Date :
  1. Date Completed 1998-05-21
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

9593789

DOI: Digital Object Identifier

10.1056/NEJM199805213382104

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.